cgp 35348 has been researched along with ethosuximide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, H; Ishige, K; Ito, Y | 1 |
| Delorey, TM; Handforth, A; Homanics, GE; Olsen, RW | 1 |
| Burnham, WM; Chan, KF; Cortez, MA; Jia, Z; Snead, OC | 1 |
| Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y | 1 |
| Gureviciene, I; Jin, N; Tanila, H; Ziyatdinova, S | 1 |
5 other study(ies) available for cgp 35348 and ethosuximide
| Article | Year |
|---|---|
Pharmacological profiles of absence seizure-induced increases in CRE- and AP-1 DNA-binding activities in gamma-butyrolactone-treated mice.
Topics: 4-Butyrolactone; Activating Transcription Factor 2; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA-Binding Proteins; Epilepsy, Absence; Ethosuximide; GABA Antagonists; Mice; Organophosphorus Compounds; Phosphinic Acids; Thalamus; Transcription Factor AP-1; Transcription Factors | 1998 |
Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anticonvulsants; Baclofen; Cerebral Cortex; Disease Models, Animal; Electrodes, Implanted; Electroencephalography; Ethosuximide; Female; GABA Agonists; GABA Antagonists; Humans; Male; Mice; Mice, Mutant Strains; Neural Pathways; Organophosphorus Compounds; Parietal Lobe; Receptors, GABA-A; Thalamus | 2005 |
GABAB receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures.
Topics: Animals; Anticholesteremic Agents; Anticonvulsants; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Absence; Ethosuximide; Female; GABA Antagonists; GABA-B Receptor Antagonists; Hippocampus; Learning Disabilities; Maze Learning; Memory Disorders; Organophosphorus Compounds; Rats; Time Factors; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride | 2006 |
Infantile spasms and Down syndrome: a new animal model.
Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; Electroencephalography; Ethosuximide; GABA Agonists; Genotype; Humans; Infant; Mice; Mice, Mutant Strains; Organophosphorus Compounds; Phenotype; Receptors, GABA-A; Receptors, GABA-B; Spasms, Infantile; Time Factors; Valproic Acid; Vigabatrin | 2009 |
Response of spike-wave discharges in aged APP/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Alzheimer Disease; Animals; Anticonvulsants; Atropine; Disease Models, Animal; Donepezil; Drug Administration Schedule; Electroencephalography; Epilepsy; Ethosuximide; GABA Antagonists; Humans; Injections, Intraperitoneal; Lactic Acid; Levetiracetam; Male; Mice; Mice, Transgenic; Nootropic Agents; Organophosphorus Compounds; Parasympatholytics; Plaque, Amyloid; Pyruvic Acid; Video Recording | 2020 |